Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2021 May 1;96(5):E175-E179.
doi: 10.1002/ajh.26136. Epub 2021 Mar 11.

A Phase I dose-escalation study of DCLL9718S, an antibody-drug conjugate targeting C-type lectin-like molecule-1 (CLL-1) in patients with acute myeloid leukemia

Naval Daver  1 , Amandeep Salhotra  2 , Joseph M Brandwein  3 , Nikolai A Podoltsev  4 , Daniel A Pollyea  5 , Joseph G Jurcic  6 , Sarit Assouline  7 , Karen Yee  8 , Mengsong Li  9 , Tony Pourmohamad  9 , Divya Samineni  9 , Teiko Sumiyoshi  9 , Anjali Vaze  9 , Randall C Dere  9 , Connie Ma  9 , James Cooper  9
Affiliations
Clinical Trial

A Phase I dose-escalation study of DCLL9718S, an antibody-drug conjugate targeting C-type lectin-like molecule-1 (CLL-1) in patients with acute myeloid leukemia

Naval Daver et al. Am J Hematol. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

Naval Daver: Has received research funding from Daiichi‐Sankyo, Bristol‐Myers Squibb, Pfizer, Gilead, Sevier, Genentech, Astellas, Daiichi‐Sankyo, Abbvie, Hanmi, Trovagene, FATE, Amgen, Novimmune, Glycomimetics, and ImmunoGen and has served in a consulting or advisory role for Daiichi‐Sankyo, Bristol‐Myers Squibb, Pfizer, Novartis, Celgene, AbbVie, Astellas, Genentech, Immunogen, Servier, Syndax, Trillium, Gilead, Amgen and Agios.

Amandeep Salhotra: Research funding from: BMS/Celgene. Ad Board: Syros. Consultancy: Kadmon.

Joseph Brandwein: Consulted for and received honoraria from Pfizer, Celgene/Bristol‐Myers Squib, Jazz, Abbvie, Astellas, Amgen, Taiho, Roche, Novartis, Teva.

Nikolai Podoltsev: Consulted for and received honoraria from Alexion, Pfizer, Agios Pharmaceuticals, Blueprint Medicines, Incyte, Novartis, Celgene, Bristol‐Myers Squib, CTI BioPharma, PharmaEssentia. Received research funding (all to the institution) from Boehringer Ingelheim, Astellas Pharma, Daiichi Sankyo, Sunesis Pharmaceuticals, Jazz Pharmaceuticals, Pfizer, Astex Pharmaceuticals, CTI biopharma, Celgene, Genentech, AI Therapeutics, Samus Therapeutics, Arog Pharmaceuticals, Kartos Therapeutics.

Daniel Pollyea: receives research funding from Abbvie and serves as a consultant for Abbvie, Celgene, Genentech, Novartis, Karyopharm, Syndax, Takeda, Bristol Myers Squibb, Syros, Kiadis.

Joseph Jurcic: Research funding (institutional) from: AbbVie, Arog Pharmaceuticals, Astellas Pharma, Celgene, Daiichi‐Sankyo, Forma Therapeutics, Genentech, Kuro Oncology, PTC Therapeutics, Syros Pharmaceuticals. Consultant for: AbbVie, AstraZeneca, Celgene/BMS, Daiichi‐Sankyo, Incyte, and Novartis.

Sarit Assouline: serves as a consultant for Abbvie, Astra Zeneca, Roche, Janssen.

Karen Yee: Consulted for and received honorarium from Novartis, F. Hoffmann La Roche, Takeda, Pfizer, TaiHo, Bristol‐Myers Squib/Celgene, Paladin, Astex, and Otsuka. Received research funding from Astex, Novartis, Forma Therapeutics, Jazz, Onconova, F. Hoffmann La Roche, Genentech, and Tolero.

Mengsong Li: Employee of Genentech, Inc., shareholder of F. Hoffmann La Roche, Ltd.

Tony Pourmohamad: Employee of Genentech, Inc., shareholder of F. Hoffmann La Roche, Ltd.

Divya Samineni: Employee of Genentech, Inc., shareholder of F. Hoffmann La Roche, Ltd.

Teiko Sumiyoshi: Employee of Genentech, Inc., shareholder of F. Hoffmann La Roche, Ltd.

Anjali Vaze: Employee of Genentech, Inc., shareholder of F. Hoffmann La Roche, Ltd.

Randall Dere: Employee of Genentech, Inc., shareholder of F. Hoffmann La Roche, Ltd.

Connie Ma: Employee of Genentech, Inc., shareholder of F. Hoffmann La Roche, Ltd.

James Cooper: Employee of Genentech, Inc., shareholder of F. Hoffmann La Roche, Ltd.

Figures

FIGURE 1
FIGURE 1
Waterfall plot showing patient‐level changes in marrow blasts by dose cohort. For columns not marked by BMA or BMB, changes in blast levels were calculated from peripheral blood. *Patient did not meet criteria for response. Bone marrow aspirate demonstrated 25% increased blasts. BMA, bone marrow aspirate; BMB, bone marrow biopsy
See this image and copyright information in PMC

References

    1. Bakker AB, van den Oudenrijn S, Bakker AQ, et al. C‐type lectin‐like molecule‐1: a novel myeloid cell surface marker associated with acute myeloid leukemia. Cancer Res. 2004;64:8443‐8450. - PubMed
    1. van Rhenen A, van Dongen GA, Kelder A, et al. The novel AML stem cell associated antigen CLL‐1 aids in discrimination between normal and leukemic stem cells. Blood. 2007;110:2659‐2666. - PubMed
    1. Hartley JA. The development of pyrrolobenzodiazepines as antitumour agents. Expert Opin Investig Drugs. 2011;20:73344. - PubMed
    1. Hartley JA, Hamaguchi A, Suggitt M, Gregson SJ, Thurston DE, Howard PW. DNA interstrand cross‐linking and in vivo antitumor activity of the extended pyrrolo[2,1‐c][1,4]benzodiazepine dimer SG2057. Invest New Drugs. 2012;30:950‐958. - PubMed
    1. Cheson BD, Bennett JM, Kopecky KJ, et al. Revised recommendations of the International Working Group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia. J Clin Oncol. 2003;21:4642‐4649. - PubMed

Publication types

MeSH terms

Associated data